Leme Pharmaceuticals' injection of sodium methamphetron sodium sodium sodium has been approved for the market.

Guide: Injection of sodium methamphetate is a synthetic glucoticoid.
. On August 14, Guangxi Ganzhou Zhongheng Group Co., Ltd. announced that its controlling subsidiary, Chongqing Lemei Pharmaceutical Co., Ltd. ("Leme Pharmaceuticals"), had recently received a "Drug Registration Certificate" for sodium methamphetate for injections approved by the State Drug Administration.
Pharmaceuticals submitted an application for registration and acceptance of sodium sodium acetate for injection to the State Food and Drug Administration in August 2013.
injection of sodium methamphetrone is a synthetic glucoticoid developed by Pharmacia and UPJOHN, now part of Pfizer, and first listed in the United States in 1959 under the name SOLU-MEDROL.
Is mainly used for anti-inflammatory treatment (e.g. rheumatoid diseases, primary diseases, skin diseases, etc.), immunosuppressive therapy (organ transplantation), blood diseases (access to hemolytic anemia, adult spontaneous plate plate plate reduction cyanosis, adult secondary hair plate plate reduction, etc.), tumors (adult leukemia and lymphoma, palliative treatment of acute childhood leukemia), shock therapy, endocrine disorders.
sodium acetacythate is easily soluble in water for intravenous or intramuscular injection, rapid hydrolysis in plasma, and pharmacological effects in the form of free meth nylon.
, in addition to the pharmacological effects of glucosticoids, there are stronger anti-inflammatory effects and weaker water and sodium retention.
.